Sanofi replaces chief Paul Hudson with Merck executive
Digest more
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...
Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.
Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...
Merck to present data across multiple genitourinary cancers from several approved and investigational medicines at 2026 ASCO GU cancers symposium: Rahway, New Jersey Saturday, Feb ...
Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total ...
In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...
Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...
But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...
In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...
Stocktwits on MSN
IBRX stokes retail chatter — investors see Anktiva beat Merck’s Keytruda with approval in EU
In December 2025, the European Medicines Agency recommended a conditional marketing authorization for Anktiva. ・Anktiva in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results